Please login to the form below

Not currently logged in
Email:
Password:

momelotinib

This page shows the latest momelotinib news and features for those working in and with pharma, biotech and healthcare.

Another late-stage setback tarnishes Gilead's R&D lustre

Another late-stage setback tarnishes Gilead's R&D lustre

Gilead has suffered another late-stage pipeline blow, posting lacklustre data for momelotinib – a would-be rival to Incyte/Novartis' blockbuster Jakafi/Jakavi. ... drug. A better profile against anaemia was held up as a key differentiator when Gilead

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics